Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors, Type II
  • Anemia, Sideroblastic* / drug therapy
  • Humans
  • Immunoglobulin Fc Fragments
  • Myelodysplastic Syndromes* / drug therapy


  • luspatercept
  • Activin Receptors, Type II
  • Immunoglobulin Fc Fragments

Associated data